Biopharma Daily Stock Updates - 01/11/21

Updated: Jan 13

$XBI $148.06 (-0.99%) 📉


COVID:

$HGEN (+7.61%) - Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

https://www.humanigen.com/press/Humanigen-and-EVERSANA-Announce-Partnership-to-Support-the-Launch-and-Commercialization-of-Lenzilumab-for-the-Treatment-of-COVID-19



FINANCIALS:

$HRTX (-1.83%) - Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-highlights-progress-pain-management-and-1


$ZNGX (-3.44%) - Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales

https://zogenixinc.gcs-web.com/news-releases/news-release-details/zogenix-announces-preliminary-unaudited-fourth-quarter-2020-net



PIPELINE:

$ADVM (+2.44%) - Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook

https://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-completes-patient-enrollment-infinity


$CARA (+2.63%) - Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica

http://ir.caratherapeutics.com/news-releases/news-release-details/cara-initiates-phase-2-trial-oral-korsuvatm-treatment-pruritus


CYTK (-7.19%) - CYTOKINETICS GRANTED ORPHAN DRUG DESIGNATION FOR CK-3773274 FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-granted-orphan-drug-designation-ck-3773274


$AERI (-1.07%) - Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%

https://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-receives-european-commission-approval-0


$EDIT (-15.06%) - Editas Medicine Reports On Recent Progress And Outlook At J.P. Morgan Healthcare Conference & IND Acceptance

https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-reports-recent-progress-and-outlook-jp-morgan


$ORIC (+1.66%) - ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones

https://investors.oricpharma.com/news-releases/news-release-details/oric-pharmaceuticals-provides-corporate-update-and-highlights


$APVO (-3.31%) - Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial

https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-provides-update-ongoing-apvo436-phase-1-1


$INFI (+8.16%) - Infinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium

https://investors.infi.com/news-releases/news-release-details/infinity-pharmaceuticals-announces-mario-275-phase-2-data


$MGTA (+2.26%) - Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials

https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-highlights-recent-progress-and-expected


$ORTX (-6.28%) - Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene Therapy and Expansion of its Clinical Applications

https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-2021-corporate-priorities


$WVE (-6.96%) - Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications

https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-highlights-pipeline-progress-and-expansion



0 comments

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon